EP203 - Clinical Features and Treatment Results of Inflammatory Choroidal Neovascular Membranes






ATES Halil


To present clinical features of inflammatory choroidal neovascularization (iCNV) and investigate the effectiveness and safety of the treatment.


Data of 11 eyes of 11 uveitic patients who underwent intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection and/or photodynamic therapy (PDT) for iCNV in our clinic between November 2008 and May 2022 were analyzed. Primary diagnosis, best corrected visual acuity (BCVA), iCNV charecteristics on spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA), treatment modalities, number of intravitreal anti-VEGF injections and side effects were evaluated.


The mean age of 11 (7 female and 4 male) patients was 36.6±21.6 (11-78) years. The primary diagnosis was multifocal choroiditis in 4 (36.4%), panuveitis in 4 (36.4%), toxoplasma chorioretinitis in 2 (18.2%) and histoplasmosis in 1 (9 %) patients. All patients were on systemic treatment and their uveitis was in inactive stage. Sudden loss of vision and metamorphopsia were the most common symptoms of the patients. Based on the FA findings, all iCNVs were classic type, and when 7 (63.6%) of them located in the juxtafoveal region, 4 (36.4%) were placed peripapillary. According to SD-OCT, all eyes ( 100.0 %) demonstrated Type 2 features accompanied with findings (subretinal fluid, increase in retinal thickness and intraretinal cysts) of active choroidal neovascularization. The mean number of anti-VEGF injections was 3.2±2.3 (1-9). Intravitreal injections were combined with PDT in 2 (22.2%) eyes. The pre-treatment mean BCVA was 0.7±0.5 (0.00- 1.30) logMAR and increased to 0.3±0.3 (0.00-0.40) logMAR at the post-treatment last visit (p<0.05). No serious side effects were observed in any of the cases during 31.2±24.7 (6-72) months of the post-treatment follow up period.


ICNV is a rare but sight threatening serious condition that affect the uveitic patients. Usage of anti-VEGF agents alone or combined with PDT seems to be a safe and effective treatment option for improvement and preservation of the visual acuity in these patients.

Back to Calendar

IUSG Office, Rue de L'Industrie 24, B-1040 Brussels, Belgium - VAT: BE 725 942 753